ImageneBio (IMA) Q2 2025 earnings summary

Executive summary

• Entered into a merger agreement with Inmagene Biopharmaceuticals, with stockholder approval obtained in July 2025; closing expected by end of July, subject to remaining conditions.

• Discontinued development of IK-930 and began winding down IK-595 clinical program in July 2025, shifting focus to strategic alternatives and asset divestitures.

• If the merger closes, the combined company will focus on Inmagene's lead candidate, IMG-007, for atopic dermatitis and immunology indications.

Financial highlights

• Net loss for Q2 2025 was $2.8 million, a significant improvement from $13.8 million in Q2 2024.

• Net loss for the six months ended June 30, 2025 was $11.4 million, compared to $29.9 million for the same period in 2024.

• Operating expenses for Q2 2025 decreased 45% year-over-year to $8.8 million, driven by lower R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $95.6 million as of June 30, 2025.

Outlook and guidance

• Future operations are highly dependent on successful completion of the merger and concurrent $75 million financing.

• If the merger is not completed, the board may pursue dissolution and liquidation.

• No active product development is ongoing; future R&D will depend on merger outcome.